Despite the observed decreased in tumor-derived Gas6 in advanced breast cancers, targeting stromal Gas6 and its receptors remains a promising therapeutic approach and may be valuable when combined with immunotherapies40,48. The gene discussed is GAS6; the disease is neoplasm.